Scholar Rock Holding (SRRK) Profit After Tax (2017 - 2026)
Scholar Rock Holding (SRRK) recorded quarterly Profit After Tax of -$105.5 million in Q1 2026, down 15.99% quarter-over-quarter from -$91.0 million in Q4 2025, and down 41.2% on a YoY basis from -$179.4 million in Q1 2025.
Scholar Rock Holding (SRRK) Profit After Tax (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Profit After Tax history runs 10 years deep, the most recent figure standing at -$105.5 million for Q1 2026.
- In Q1 2026, Profit After Tax fell 41.2% year-over-year to -$105.5 million; the TTM figure through Mar 2026 stood at -$408.7 million (down 54.72% YoY), while the FY2025 annual figure was -$377.9 million, down 53.45% from the prior year.
- Profit After Tax was -$105.5 million for Q1 2026 at Scholar Rock Holding, down from -$91.0 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$8.0 million in Q1 2022 to a low of -$110.0 million in Q2 2025.
- Historically, Profit After Tax has averaged -$60.6 million across 5 years, with a median of -$56.9 million in 2024.
- The sharpest annual moves came in 2022 and 2023: Profit After Tax jumped 71.27% in 2022, then plunged 395.33% in 2023.
- A 5-year view of Profit After Tax shows it stood at -$39.3 million in 2022, then retreated by 17.5% to -$46.1 million in 2023, then slumped by 44.07% to -$66.5 million in 2024, then plunged by 36.88% to -$91.0 million in 2025, then declined by 15.99% to -$105.5 million in 2026.
- The last three Profit After Tax figures came in at -$105.5 million (Q1 2026), -$91.0 million (Q4 2025), and -$102.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.74 Mn |
| 10 | Scholar Rock Holding | 6.03 Bn | 5.55 Bn | - | -105.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -105.51 Mn |
| Dec 31, 2025 | -90.97 Mn |
| Sep 30, 2025 | -102.22 Mn |
| Jun 30, 2025 | -110.03 Mn |
| Mar 31, 2025 | -74.72 Mn |
| Dec 31, 2024 | -66.45 Mn |
| Sep 30, 2024 | -64.48 Mn |
| Jun 30, 2024 | -58.51 Mn |
| Mar 31, 2024 | -56.85 Mn |
| Dec 31, 2023 | -46.13 Mn |
| Sep 30, 2023 | -42.36 Mn |
| Jun 30, 2023 | -37.93 Mn |
| Mar 31, 2023 | -39.38 Mn |
| Dec 31, 2022 | -39.26 Mn |
| Sep 30, 2022 | -43.30 Mn |
| Jun 30, 2022 | -44.00 Mn |
| Mar 31, 2022 | -7.95 Mn |
| Dec 31, 2021 | -35.91 Mn |
| Sep 30, 2021 | -37.51 Mn |
| Jun 30, 2021 | -30.71 Mn |